D
Debut Biotech
Creating advanced continuous manufacturing approaches for the production of small and large molecules harnessing the power of biocatalysis
About Debut Biotech
Debut Biotech is a unique startup operating in the biotechnology sector. The company positions itself as an "Unconventional Innovation Lab," focusing on creating solutions that are climate positive, people positive, and overall positive. This means that their innovations are designed to benefit the environment, the people, and the world at large.
Debut Biotech operates in the market of biotechnology, a field that uses biological processes, organisms, or systems to manufacture products. Their clients are likely to be companies in industries such as pharmaceuticals, agriculture, and environmental conservation, who are looking for innovative biotech solutions.
Their business model revolves around using their expertise in biotechnology to develop and sell innovative solutions. They make money by selling these solutions to their clients. The company's focus on being climate positive and people positive suggests that they prioritize creating solutions that are environmentally friendly and beneficial to people, which could make them attractive to companies that share these values.
In summary, Debut Biotech is a biotech startup that develops and sells innovative, environmentally friendly, and people-friendly solutions to companies in various industries.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Diego, United States
- Employees
- 100
- Open positions
- 7
- Dealroom signal
- 84.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Synthetic Biology, Spinout, Industrial Technology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Aug 2025 | $20M | $200M | Sandbox Industries · Material Impact · GS Futures · Fine Structure Ventures | ↗ |
| SERIES BOther financing | Jun 2023 | $40M | $160M | Cultivian Sandbox Ventures · Material Impact · GS Futures · ACVC Ventures | ↗ |
Growth signals
Latest recorded traffic for Debut Biotech is 2.3K monthly website visits, down 41% over the last three months. Debut Biotech's team grew 14.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Better Ventures
KdT Ventures
SpringTide
FTW Ventures
Air Force Research Lab
Series A10 investors entered at this stage
Material Impact
Cantos Ventures
Humboldt Fund
Fine Structure Ventures
Cultivian Sandbox Ventures
ACVC
L'Oreal BOLD
GS Futures
ACVC Ventures
Cavallo Ventures
Series B and later3 investors entered at this stage
Sandbox Industries
WealthBerry Labs
EDBI
Other known investors1 additional known investor
University of California, Irvine
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Debut Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Debut Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.